Genomics sequencing company Illumina partnered with big pharma AstraZeneca for a research collaboration to advance drug discovery using artificial intelligence (AI)-based genomic analysis.
The partnership will allow AstraZeneca to leverage Illumina’s AI-based tools PrimateAI and SpliceAI, along with AstraZeneca’s AI program Jarvis, to examine and interpret genomic data. Specifically, AstraZeneca's Centre for Genomics Research will use the combined tools to analyze data from its digital biobanks to more accurately identify genetic variants that could be linked to diseases, which would help develop more effective and safer treatments.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.